SecBot SecBot
SECBOTREPLAY Home › Report › WGS

WGS · Q3 adj EPS $0.28 vs $0.07 est

GeneDx Holdings Corp. · 8-K filed Nov 9, 2026 at 16:10 ET

At the news

BULLISHIMPACT 6/10

8-K filed Nov 9, 2026 at 16:10 ET

GeneDx reported Q3 2026 revenue of $123.1M (+5% YoY) and adjusted EPS of $0.28, beating the $0.07 consensus. Exome and genome revenue grew 12% YoY to $110.4M on 25% volume growth. Full-year revenue guidance was reiterated at $475M-$490M, but exome and genome volume growth guidance was trimmed to at least 28% from at least 30%.

  • Q3 2026 total revenue $123.1M, +5% YoY
  • Exome and genome revenue $110.4M, +12% YoY
  • Exome and genome volume 32,134, +25% YoY
  • Adjusted diluted EPS $0.28 vs consensus $0.07

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access